File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/ctg.2017.51
- Scopus: eid_2-s2.0-85042104714
- PMID: 29072673
- WOS: WOS:000414996200004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels
Title | Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels |
---|---|
Authors | |
Issue Date | 2017 |
Publisher | Nature Publishing Group: Open Access Journals - Option A. The Journal's web site is located at http://www.nature.com/ctg/index.html |
Citation | Clinical and Translational Gastroenterology, 2017, v. 8 n. 10, article no. e125, p. 1-7 How to Cite? |
Abstract | OBJECTIVES: We aimed to determine the levels of alanine aminotransferase (ALT), hepatitis B virus DNA (HBV DNA), HBsAg, and a novel viral marker (hepatitis B core-related antigen (HBcrAg)); hepatitis B e antigen (HBeAg) seroconversion and drug resistance rates after 7 years of entecavir treatment in chronic hepatitis B (CHB) patients.
METHODS: Two hundred and twenty-two Chinese CHB patients on continuous entecavir treatment were recruited. Serologic, virologic, biochemical outcomes, and the occurrence of entecavir signature mutations were determined.
RESULTS: The rates of ALT normalization, HBeAg seroconversion, and undetectable HBV DNA were 98.3%, 82.1%, and 98.7%, respectively, after 7 years of entecavir treatment. The genotypic resistance rate was 1.2%. Decline of HBsAg level was modest with a median decline rate of 0.107 log IU/ml/year. Among patients with baseline HBsAg <1,000 IU/ml and annual HBsAg decline rate of ≥0.166 log IU/ml, all have HBsAg of <200 IU/ml (a level highly predictive for HBsAg seroclearance) at year 7. In contrast, in patients with baseline HBsAg ≥1,000 IU/ml and annual HBsAg decline rate of <0.166 log IU/ml, 95.5% had HBsAg of ≥200 IU/ml at year 7. Decline of HBcrAg levels was moderate with a median decline rate of 0.244 log kU/ml/year. Forty-seven patients (32.0%) had undetectable HBcrAg level at year 7.
CONCLUSIONS: Long-term entecavir therapy continued to have good responses with low drug resistance rate. However, the decline of HBsAg with treatment was suboptimal. HBcrAg level declined at a relatively better rate. Baseline HBsAg level of <1,000 IU/ml and annual decline of 0.166 log IU/ml could be used to predict HBsAg response. |
Persistent Identifier | http://hdl.handle.net/10722/252162 |
ISSN | 2023 Impact Factor: 3.0 2023 SCImago Journal Rankings: 1.413 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lam, YF | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Yuen, JCH | - |
dc.contributor.author | Chong, CK | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2018-04-11T07:25:18Z | - |
dc.date.available | 2018-04-11T07:25:18Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Clinical and Translational Gastroenterology, 2017, v. 8 n. 10, article no. e125, p. 1-7 | - |
dc.identifier.issn | 2155-384X | - |
dc.identifier.uri | http://hdl.handle.net/10722/252162 | - |
dc.description.abstract | OBJECTIVES: We aimed to determine the levels of alanine aminotransferase (ALT), hepatitis B virus DNA (HBV DNA), HBsAg, and a novel viral marker (hepatitis B core-related antigen (HBcrAg)); hepatitis B e antigen (HBeAg) seroconversion and drug resistance rates after 7 years of entecavir treatment in chronic hepatitis B (CHB) patients. METHODS: Two hundred and twenty-two Chinese CHB patients on continuous entecavir treatment were recruited. Serologic, virologic, biochemical outcomes, and the occurrence of entecavir signature mutations were determined. RESULTS: The rates of ALT normalization, HBeAg seroconversion, and undetectable HBV DNA were 98.3%, 82.1%, and 98.7%, respectively, after 7 years of entecavir treatment. The genotypic resistance rate was 1.2%. Decline of HBsAg level was modest with a median decline rate of 0.107 log IU/ml/year. Among patients with baseline HBsAg <1,000 IU/ml and annual HBsAg decline rate of ≥0.166 log IU/ml, all have HBsAg of <200 IU/ml (a level highly predictive for HBsAg seroclearance) at year 7. In contrast, in patients with baseline HBsAg ≥1,000 IU/ml and annual HBsAg decline rate of <0.166 log IU/ml, 95.5% had HBsAg of ≥200 IU/ml at year 7. Decline of HBcrAg levels was moderate with a median decline rate of 0.244 log kU/ml/year. Forty-seven patients (32.0%) had undetectable HBcrAg level at year 7. CONCLUSIONS: Long-term entecavir therapy continued to have good responses with low drug resistance rate. However, the decline of HBsAg with treatment was suboptimal. HBcrAg level declined at a relatively better rate. Baseline HBsAg level of <1,000 IU/ml and annual decline of 0.166 log IU/ml could be used to predict HBsAg response. | - |
dc.language | eng | - |
dc.publisher | Nature Publishing Group: Open Access Journals - Option A. The Journal's web site is located at http://www.nature.com/ctg/index.html | - |
dc.relation.ispartof | Clinical and Translational Gastroenterology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels | - |
dc.type | Article | - |
dc.identifier.email | Lam, YF: fyflam@hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Yuen, JCH: jchyuen@hkucc.hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Cheung, KSM=rp02532 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1038/ctg.2017.51 | - |
dc.identifier.pmid | 29072673 | - |
dc.identifier.pmcid | PMC5666122 | - |
dc.identifier.scopus | eid_2-s2.0-85042104714 | - |
dc.identifier.hkuros | 284782 | - |
dc.identifier.volume | 8 | - |
dc.identifier.issue | 10 | - |
dc.identifier.spage | article no. e125, p. 1 | - |
dc.identifier.epage | article no. e125, p. 7 | - |
dc.identifier.isi | WOS:000414996200004 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 2155-384X | - |